Inverse ETFs were designed to return the exact opposite of their underlying benchmarks on a daily basis. But as hedges against market pullbacks, they have drawbacks. Read More
Scott Chan moved from China to the U.S. with family at the age of ten. He passed the rigorous entrance exam and attended the merit-based Stuyvesant High School, widely held to be best public school in New York City. He earned undergraduate degrees from New York University followed by an MBA degree from the Zicklin School of Business at Baruch College.
Shortly thereafter Scott partnered with Dr. Stephen Leeb on numerous financial publications. Today, he serves as the lead analyst for Real World Investing and The Complete Investor.
Mr. Chan is an avid baseball fan and enjoys outdoor activities in his spare time. A multicultural person, he reads Chinese and speaks fluent Mandarin and Cantonese Chinese.
Analyst Articles
Options offer the potential to make much greater gains in a short amount of time compared to the underlying stock. Let's take a basic look at how they are priced. Read More
Many traders analyze stock charts to guide them in their trading decisions. We take a basic look at how understanding resistance and support levels can help a trader make money. Read More
Align Technology's orthodontia breakthrough proves that innovation doesn’t have to be fancy to be profitable. But can the firm handle the influx of competitors? Read More
If you want fast growth, but you also want income, there’s a way even if you hold a portfolio of mostly non-dividend payers: selling options. Read More
Schlumberger is a leading oilfield services company with a global reach, but falling oil prices have weighed on the stock. Can Schlumberger come back? Read More
Dubbed the "Netflix of China," iQIYI is a leading provider of video streaming content in China, a vast market for the company's services. Will the stock take off this year? Read More
Nike is one of the most recognizable brands in the world. The company has faced some stiff competition lately. Will it remain Number One? Read More
The last few years have been rough for biotech stocks, but Amgen has been a notable exception. It's now facing new threats from biosimilars. Can it continue to outperform? Read More
Multiple sclerosis, commonly referred to as MS, is a debilitating disease of the central nervous system. MS affects about 2.3 million people worldwide. Symptoms can range from tingling and numbness to blindness and paralysis. They can vary greatly from one patient to another, and sometimes even in the same… Read More